PISCATAWAY, NJ, Aug. 15, 2013 (GLOBE NEWSWIRE) -- InnoPharma, Inc. today announced the launch of acamprosate calcium, 333 mg delayed-release tablets (generic equivalent of Campral®). InnoPharma developed the generic formulation of acamprosate delayed-release tablets and entered into an agreement with Glenmark Pharmaceuticals, Inc. pursuant to which Glenmark will sell, market and distribute acamprosate in the United States.
Acamprosate calcium is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.
Campral® is marketed in the United States by Forest Laboratories, Inc. and is a registered trademark owned by Merck Sante, Lipha, Lyonnaise Industrielle Pharmaceutique.
About InnoPharma, Inc.
InnoPharma is a sterile product development company, focused on developing complex generic and innovative specialty pharmaceutical products in injectable and ophthalmic dosage forms. The Company has a broad portfolio of products under development, with formulations including solutions, suspension, lyophilized, emulsions, liposomes, micelles and lipid complexes. InnoPharma's pipeline includes small molecules with solubility and stability challenges, as well as difficult to produce and characterize polypeptides and carbohydrates. The Company has a comprehensive infrastructure for the development of its products in its state of the art R&D facilities in New Jersey, with the capability to handle potent and cytotoxic molecules. More information can be found at www.innopharmainc.com.
About Glenmark Generics Limited
Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America and is developing an EU presence. It primarily sells its FDF products in the United States (US) and the European Union (EU), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 80 countries, including the US, various countries in the EU, South America and India.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, some of which are outside management's control, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions identify forward-looking statements, although not all forward-looking statements contain these identifying words. InnoPharma, Inc. undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
CONTACT: John C. Deighan, CFO InnoPharma, Inc. (732) 885-2939 email@example.com